TOTAL COST OF CARE ANALYSIS OF FIRST-LINE IMMUNO-ONCOLOGY THERAPIES FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: A COLOMBIAN PAYER PERSPECTIVE
Author(s)
Camilo Tamayo, BA1, Diana Castaño, MD2.
1AstraZeneca, Bogotá, Colombia, 2AstraZeneca, Bogota, Colombia.
1AstraZeneca, Bogotá, Colombia, 2AstraZeneca, Bogota, Colombia.
OBJECTIVES: Tremelimumab plus durvalumab (STRIDE) and atezolizumab plus bevacizumab are guideline-recommended first-line immuno-oncology (IO) regimens for patients with unresectable hepatocellular carcinoma (uHCC). This study aims to quantify and compare the total economic burden associated with the management of uHCC patients treated with STRIDE versus atezolizumab plus bevacizumab, adapting an existing cost-of-care framework to reflect the Colombian healthcare system and payer perspective.
METHODS: A cost-of-care model was adapted to compare drug-related costs (treatment acquisition and administration) and non-drug-related costs, including healthcare resource utilization, endoscopy procedures, and management of grade ≥3 treatment-emergent adverse events (TEAEs). The analysis focused on uHCC patients eligible for first-line IO therapy, defined as Barcelona Clinic Liver Cancer (BCLC) stage C patients with Child‑Pugh A, or BCLC stage B patients with Child‑Pugh A who were not candidates for locoregional therapies. Clinical inputs, including treatment duration and TEAEs rates, were derived from the HIMALAYA and IMbrave150 trials. Resource use patterns were obtained from published literature and local clinical practice. Unit costs were adapted using Colombian tariff manuals and databases and subsequently converted to US dollars.
RESULTS: From a Colombian payer perspective, there was an average cost savings of USD$10.766,65 per patient per year when patients were treated with STRIDE compared with atezolizumab plus bevacizumab. The main drivers of cost savings were, lower drug acquisition cost (-8%), drug administration (-59%), TEAE management (-70%) and lower costs associated with endoscopy (-100%) and. The incremental annual cost offset to the health plan was USD$1.937.997 per year when treated with STRIDE.
CONCLUSIONS: This is the first study that holistically captures the annual cost of treating uHCC patients in Colombia. This findings suggests that STRIDE offers cost savings for uHCC treatment in the Colombian healthcare system. Additional real-world evidence studies are warranted to confirm the long-term survival benefits and associated treatment costs.
METHODS: A cost-of-care model was adapted to compare drug-related costs (treatment acquisition and administration) and non-drug-related costs, including healthcare resource utilization, endoscopy procedures, and management of grade ≥3 treatment-emergent adverse events (TEAEs). The analysis focused on uHCC patients eligible for first-line IO therapy, defined as Barcelona Clinic Liver Cancer (BCLC) stage C patients with Child‑Pugh A, or BCLC stage B patients with Child‑Pugh A who were not candidates for locoregional therapies. Clinical inputs, including treatment duration and TEAEs rates, were derived from the HIMALAYA and IMbrave150 trials. Resource use patterns were obtained from published literature and local clinical practice. Unit costs were adapted using Colombian tariff manuals and databases and subsequently converted to US dollars.
RESULTS: From a Colombian payer perspective, there was an average cost savings of USD$10.766,65 per patient per year when patients were treated with STRIDE compared with atezolizumab plus bevacizumab. The main drivers of cost savings were, lower drug acquisition cost (-8%), drug administration (-59%), TEAE management (-70%) and lower costs associated with endoscopy (-100%) and. The incremental annual cost offset to the health plan was USD$1.937.997 per year when treated with STRIDE.
CONCLUSIONS: This is the first study that holistically captures the annual cost of treating uHCC patients in Colombia. This findings suggests that STRIDE offers cost savings for uHCC treatment in the Colombian healthcare system. Additional real-world evidence studies are warranted to confirm the long-term survival benefits and associated treatment costs.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE374
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology